全文获取类型
收费全文 | 10982篇 |
免费 | 1068篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 65篇 |
儿科学 | 288篇 |
妇产科学 | 195篇 |
基础医学 | 1515篇 |
口腔科学 | 253篇 |
临床医学 | 1182篇 |
内科学 | 1969篇 |
皮肤病学 | 223篇 |
神经病学 | 1105篇 |
特种医学 | 382篇 |
外科学 | 1750篇 |
综合类 | 270篇 |
一般理论 | 6篇 |
预防医学 | 1180篇 |
眼科学 | 261篇 |
药学 | 856篇 |
中国医学 | 13篇 |
肿瘤学 | 557篇 |
出版年
2023年 | 52篇 |
2021年 | 153篇 |
2020年 | 114篇 |
2019年 | 213篇 |
2018年 | 236篇 |
2017年 | 182篇 |
2016年 | 154篇 |
2015年 | 211篇 |
2014年 | 262篇 |
2013年 | 412篇 |
2012年 | 675篇 |
2011年 | 678篇 |
2010年 | 342篇 |
2009年 | 333篇 |
2008年 | 612篇 |
2007年 | 627篇 |
2006年 | 694篇 |
2005年 | 602篇 |
2004年 | 578篇 |
2003年 | 504篇 |
2002年 | 495篇 |
2001年 | 270篇 |
2000年 | 226篇 |
1999年 | 235篇 |
1998年 | 157篇 |
1997年 | 117篇 |
1996年 | 95篇 |
1995年 | 86篇 |
1994年 | 84篇 |
1993年 | 90篇 |
1992年 | 176篇 |
1991年 | 181篇 |
1990年 | 138篇 |
1989年 | 150篇 |
1988年 | 133篇 |
1987年 | 149篇 |
1986年 | 134篇 |
1985年 | 144篇 |
1984年 | 107篇 |
1983年 | 107篇 |
1982年 | 68篇 |
1981年 | 55篇 |
1980年 | 72篇 |
1979年 | 90篇 |
1978年 | 72篇 |
1977年 | 72篇 |
1976年 | 52篇 |
1975年 | 57篇 |
1974年 | 69篇 |
1973年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献
3.
4.
David B. Matchar Kirsten Eom Pamela W. Duncan Mina Lee Rita Sim Nirmali R. Sivapragasam Christopher T. Lien Marcus Eng Hock Ong 《Archives of physical medicine and rehabilitation》2019,100(1):1-8
Objective
To perform a cost-effectiveness analysis of a multifactorial, tailored intervention to reduce falls among a heterogeneous group of high-risk elderly people.Design
Randomized control trial.Settings
Communities.Participants
Adults aged at least 65 years (N=354) seen at the emergency department (ED) for a fall or fall-related injury and discharged home.Interventions
The intervention group received a tailored program of physical therapy focused on progressive training in strength, balance, and gait for a period of 3 months. They also received screening and referrals for low vision, polypharmacy, and environmental hazards. The Short Physical Performance Battery (SPPB) test was assessed at regular intervals to allocate participants into either a home-based or group center-based program. The control group received usual care prescribed by a physician and educational materials on falls prevention.Main Outcome Measures
The incremental cost-effectiveness ratio (ICER) over the 9-month study period based on intervention costs and utility in terms of quality-adjusted life years (QALYs) calculated from EuroQol-5D scores.Results
The ICER was 120,667 Singapore dollars (S$) per QALY gained (S$362/0.003 QALYs), above benchmark values (S$70,000). However, the intervention was more effective and cost-saving among those with SPPB scores of greater than 6 at baseline, higher cognitive function, better vision and no more than 1 fall in the preceding 6 months. The intervention was also cost-effective among those with 0-1 critical comorbidities (S$22,646/QALY).Conclusion
The intervention was, overall, not cost-effective, compared to usual care. However, the program was cost-effective among healthier subgroups, and even potentially cost-saving among individuals with sufficient reserve to benefit. 相似文献5.
6.
7.
Duncan S. Buchan Fiona McSeveney Gillian McLellan 《Clinical physiology and functional imaging》2019,39(1):51-56
The purpose of this study was to evaluate the agreement between several activity measures using raw acceleration data from accelerometers worn concurrently on the dominant and non‐dominant wrist. Fifty‐five adults (31·9 ± 9·7 years, 26 males) wore two ActiGraph GT3X+ monitors continuously for 1 day, one on their non‐dominant wrist and the other on their dominant wrist. Paired t‐tests were undertaken with sequential Holm‐Bonferroni corrections to compare wear time, moderate‐vigorous physical activity (MVPA), time spent in 10‐min bouts of MVPA (MVPA10 min) and the average magnitude of dynamic wrist acceleration (ENMO). Level of agreement between outcome variables from the wrists was examined using intraclass correlation coefficients (ICC, single measures, absolute agreement) with 95% confidence intervals and limits of agreement (LoA). Time spent across acceleration levels in 40 mg resolution were also examined. There were no significant differences between the non‐dominant and dominant wrist for ENMO, wear time, MVPA or MVPA10 min. Agreement between wrists was strong for most outcomes (ICC ≥0·92) including wear time, ENMO, MVPA, MVPA10 min and the distribution of time across acceleration levels. Agreement was strong in the low acceleration bands (ICC = 0·970 and 0·922) with a mean bias of 3·08 min (LoA ?55·18 to 61·34) and ?5·43 (LoA ?43·47 to 32·62). In summary, ENMO, MVPA, MVPA10 min, wear time and the distribution of time across acceleration levels compared well at the group level. The LOA from the two lowest acceleration levels suggest further work over a longer monitoring period is needed to determine whether outputs from each wrist are comparable. 相似文献
8.
9.
Kendall J. Burdick Joy D. Cogan Lynette C. Rives Amy K. Robertson Mary E. Koziura Elly Brokamp Laura Duncan Vickie Hannig Jean Pfotenhauer Rena Vanzo Michael S. Paul Anna Bican Thomas Morgan Jessica Duis John H. Newman Rizwan Hamid John A. Phillips III Undiagnosed Diseases Network 《American journal of medical genetics. Part A》2020,182(6):1400-1406
While exome sequencing (ES) is commonly the final diagnostic step in clinical genetics, it may miss diagnoses. To clarify the limitations of ES, we investigated the diagnostic yield of genetic tests beyond ES in our Undiagnosed Diseases Network (UDN) participants. We reviewed the yield of additional genetic testing including genome sequencing (GS), copy number variant (CNV), noncoding variant (NCV), repeat expansion (RE), or methylation testing in UDN cases with nondiagnostic ES results. Overall, 36/54 (67%) of total diagnoses were based on clinical findings and coding variants found by ES and 3/54 (6%) were based on clinical findings only. The remaining 15/54 (28%) required testing beyond ES. Of these, 7/15 (47%) had NCV, 6/15 (40%) CNV, and 2/15 (13%) had a RE or a DNA methylation disorder. Thus 18/54 (33%) of diagnoses were not solved exclusively by ES. Several methods were needed to detect and/or confirm the functional effects of the variants missed by ES, and in some cases by GS. These results indicate that tests to detect elusive variants should be considered after nondiagnostic preliminary steps. Further studies are needed to determine the cost‐effectiveness of tests beyond ES that provide diagnoses and insights to possible treatment. 相似文献
10.